Previous Page
26
nanotimes
Companies Facts
volume weighted average share price. Austock Secu- rities Limited was the lead manager of the transaction and was assisted in the USA by Chardan Capital Mar- kets LLC. These shares have been largely subscribed for by existing shareholders under the Company’s ASX Listing Rule 7.1 capacity. Also, as set out in the Company’s Appendix 4C released on April 29, Dyesol intends to offer a Share Purchase Plan (SPP) to all shareholders as of the record date on the same price and volume terms as the above placement. The terms and conditions of the SPP offer will be sent to all eligible shareholders shortly.
Separately, Dyesol has entered an agreement with Springtree Special Opportunities Fund, LP (Spring- Tree) under which SpringTree can invest between A$15.2 million and A$22.4 million in Dyesol over the next three years in monthly instalments (the Agreement). The Agreement is structured to provi- de funding flexibility, minimise dilution to existing shareholders while relating to the share price at the time of each monthly investment. Dyesol has the ability to terminate the Agreement at any time, at no cost if the price is below a specified level or after 12 months, or otherwise at a small break fee. http://www.dyesol.com
E Ink®
Corporation and Chilin Technology Corpo- ration, a leading manufacturer of vertically inte-
grated flat panel displays, announced a partnership to bring low-power industrial and other specialized electrophoretic displays to the marketplace. The partnership makes the patented E Ink Vizplex™ imaging film available to Chilin for mass production, distribution and sales to consumers. http://www.eink.com
F
EI (NASDAQ: FEIC) has shipped the 250th Helios NanoLab™ DualBeam™ system. Since its intro-
duction in 2006, the award-winning Helios NanoLab has experienced widespread market acceptance.
“The Helios NanoLab DualBeam provides the SEM and FIB performance needed to solve some of the critical roadblocks to advancing technology and sciences across many disciplines,” said John Wil- liams, vice president of marketing, FEI. “It has been adopted by leading semiconductor manufacturers for their most advanced research and development needs; it is being used by major academic and in- dustrial research laboratories for advanced material characterization and modification down to the single nanometer scale; and it has even expanded into the life sciences and oil & gas industries due to its ability to provide three-dimensional imaging at the nanosca- le.”
lamel Technologies (NASDAQ: FLML) has entered into a license agreement with a leading specialty
pharmaceutical company for development and com- mercialization of two molecules for pain indications. Pursuant to the agreement, Flamel will receive an upfront license fee of $3 million, as well as develop- ment-based milestones, and mid-single digit royalties upon eventual product sales.
For the first quarter 2011, Flamel reported total reve- nues of $6.8 million versus $8.1 million in the year- ago period. License and research revenues during the first quarter of 2011 were $3.2 million versus $3.4 million in the first quarter 2010. Product sales and services, relating to the supply of Coreg CR which the Company has continued to furnish to GSK while
11-04 :: April/May 2011